{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T09:03:06Z","timestamp":1784624586809,"version":"3.55.0"},"reference-count":137,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Reversible genetic medicines are emerging as controllable alternatives to permanent genome editing by enabling programmable modulation of RNA sequence, transcript abundance, chromatin state, and gene expression without irreversible genomic alteration. However, reversibility is not a single binary property: transient editor exposure, decay of the molecular effect, recovery of cellular function, and clinical capacity to stop, redose, or counteract treatment may diverge. This review therefore distinguishes mechanistic, functional, and clinical reversibility while examining targeted delivery systems for RNA-editing and epigenome-editing therapeutics. Key payloads include ADAR-recruiting oligonucleotides, CRISPR-Cas13 RNA editors, guide RNAs, chemically modified RNAs, editor-encoding mRNAs, dCas9 transcriptional regulators, DNA methylation editors, histone-modifying systems, and CRISPRoff-like platforms. We evaluate extracellular and intracellular delivery barriers, including nuclease degradation, immune recognition, renal clearance, liver uptake, cellular entry, endosomal escape, cytoplasmic release, nuclear localization, chromatin access, editing-window duration, off-target activity, immunogenicity, repeat-dosing feasibility, manufacturing, quality control, potency assays, and regulatory translation. Overall, delivery systems for reversible genetic medicines should be judged by tissue selectivity, functional editing, duration of action, reversibility after treatment withdrawal, safety, manufacturability, and clinical controllability.<\/jats:p>","DOI":"10.3390\/ijms27146467","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T08:14:27Z","timestamp":1784621667000},"page":"6467","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Permanent Genome Editing: Molecular Delivery Strategies for RNA Editing and Epigenome-Editing Therapeutics"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6864-2366","authenticated-orcid":false,"given":"Wajid","family":"Zaman","sequence":"first","affiliation":[{"name":"Department of Life Sciences, Yeungnam University, Gyeongsan 38541, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7596-8513","authenticated-orcid":false,"given":"Asma","family":"Ayaz","sequence":"additional","affiliation":[{"name":"Faculty of Sports Science, Ningbo University, Ningbo 315211, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12943-021-01431-6","article-title":"Application of the CRISPR\/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1007\/s11033-021-06479-7","article-title":"CRISPR\/Cas based gene editing: Marking a new era in medical science","volume":"48","author":"Prasad","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"ref_3","first-page":"515","article-title":"A Primer on Gene Editing: What Does It Mean for Pathologists?","volume":"148","author":"Schmidt","year":"2023","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/med.21537","article-title":"Progress in the application of CRISPR: From gene to base editing","volume":"39","author":"Wu","year":"2019","journal-title":"Med. Res. Rev."},{"key":"ref_5","first-page":"318","article-title":"Mitigating the Off-target Effects in CRISPR\/Cas9-mediated Genetic Editing with Bioinformatic Technologies","volume":"3","author":"Yuan","year":"2024","journal-title":"Trans. Mater. Biotechnol. Life Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1021\/acs.bioconjchem.7b00057","article-title":"In Vivo Delivery of CRISPR\/Cas9 for Therapeutic Gene Editing: Progress and Challenges","volume":"28","author":"Mout","year":"2017","journal-title":"Bioconjugate Chem."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Wang, L., Li, F., Dang, L., Liang, C., Wang, C., He, B., Liu, J., Li, D., Wu, X., and Xu, X. (2016). In Vivo Delivery Systems for Therapeutic Genome Editing. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17050626"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Mirgayazova, R., Khadiullina, R., Chasov, V., Mingaleeva, R., Miftakhova, R., Rizvanov, A., and Bulatov, E. (2020). Therapeutic Editing of the TP53 Gene: Is CRISPR\/Cas9 an Option?. Genes, 11.","DOI":"10.3390\/genes11060704"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s41587-019-0178-z","article-title":"Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs","volume":"37","author":"Qu","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1093\/nar\/gkac123","article-title":"Determinants of heritable gene silencing for KRAB-dCas9 + DNMT3 and Ezh2-dCas9 + DNMT3 hit-and-run epigenome editing","volume":"50","author":"Tomkova","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41587-022-01225-1","article-title":"Endogenous ADAR-mediated RNA editing in non-human primates using stereopure chemically modified oligonucleotides","volume":"40","author":"Monian","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/s41587-021-01171-4","article-title":"Efficient in vitro and in vivo RNA editing via recruitment of endogenous ADARs using circular guide RNAs","volume":"40","author":"Katrekar","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41587-019-0013-6","article-title":"Precise RNA editing by recruiting endogenous ADARs with antisense oligonucleotides","volume":"37","author":"Merkle","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41587-021-01180-3","article-title":"Engineered circular ADAR-recruiting RNAs increase the efficiency and fidelity of RNA editing in vitro and in vivo","volume":"40","author":"Yi","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/s41594-025-01529-1","article-title":"Structural insights into RNA-guided RNA editing by the Cas13b\u2013ADAR2 complex","volume":"32","author":"Ishikawa","year":"2025","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Gjaltema, R.A.F., Goubert, D., Huisman, C., Tobilla, C.d.P.G., Koncz, M., Jellema, P.G., Wu, D., Brouwer, U., Kiss, A., and Verschure, P.J. (2020). KRAB-Induced Heterochromatin Effectively Silences PLOD2 Gene Expression in Somatic Cells and Is Resilient to TGF\u03b21 Activation. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21103634"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.jgg.2024.05.010","article-title":"A programmable CRISPR\/dCas9-based epigenetic editing system enabling loci-targeted histone citrullination and precise transcription regulation","volume":"51","author":"Zhang","year":"2024","journal-title":"J. Genet. Genom."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1093\/nar\/gky171","article-title":"Designer epigenome modifiers enable robust and sustained gene silencing in clinically relevant human cells","volume":"46","author":"Mlambo","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-1-0716-4051-7_14","article-title":"Protocol for Delivery of CRISPR\/dCas9 Systems for Epigenetic Editing into Solid Tumors Using Lipid Nanoparticles Encapsulating RNA","volume":"Volume 2842","author":"Woodward","year":"2024","journal-title":"Methods in Molecular Biology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/anie.201610209","article-title":"Non-Viral CRISPR\/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA","volume":"56","author":"Miller","year":"2017","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-1-0716-4051-7_13","article-title":"Plasmid Delivery and Single-Cell Plasmid Expression Analysis for CRISPR\/dCas9-Based Epigenetic Editing","volume":"Volume 2842","author":"Saparoea","year":"2024","journal-title":"Methods in Molecular Biology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/biolre\/ioaf195","article-title":"Potential of small extracellular vesicles as Cas9 delivery tool: A promising approach for gene editing livestock gametes and embryos","volume":"113","author":"Ferraz","year":"2025","journal-title":"Biol. Reprod."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/j.cell.2021.03.025","article-title":"Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing","volume":"184","author":"Nunez","year":"2021","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7948","DOI":"10.1038\/s41467-025-63167-x","article-title":"Programmable epigenome editing by transient delivery of CRISPR epigenome editor ribonucleoproteins","volume":"16","author":"Xu","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"18512","DOI":"10.1021\/jacs.4c17920","article-title":"RNA Editing-Mediated Correction of TP53 Nonsense Mutations via Lipid Nanoparticle-Delivered Circular ADAR-Recruiting RNAs","volume":"147","author":"Wang","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1126\/science.aaq0180","article-title":"RNA editing with CRISPR-Cas13","volume":"358","author":"Cox","year":"2017","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13059-026-03967-6","article-title":"Comprehensive profiling of CRISPR\/dCas9 epigenome editors indicates a complex link between on and off target effects","volume":"27","author":"Rangani","year":"2026","journal-title":"Genome Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"8849","DOI":"10.1038\/s41467-025-64434-7","article-title":"Stereo-random oligonucleotides enable efficient recruitment of ADAR in vitro and in vivo","volume":"16","author":"Pfeiffer","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jconrel.2020.06.027","article-title":"Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic lipid selection","volume":"325","author":"Lou","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jconrel.2021.09.008","article-title":"Polyplex nanomicelle delivery of self-amplifying RNA vaccine","volume":"338","author":"Chang","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41587-025-02628-6","article-title":"Improved RNA base editing with guide RNAs mimicking highly edited endogenous ADAR substrates","volume":"44","author":"Sun","year":"2026","journal-title":"Nat. Biotechnol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nature24049","article-title":"RNA targeting with CRISPR\u2013Cas13","volume":"550","author":"Abudayyeh","year":"2017","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41587-021-01030-2","article-title":"Compact RNA editors with small Cas13 proteins","volume":"40","author":"Kannan","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1620\/tjem.2023.J011","article-title":"A New Method for Programmable RNA Editing Using CRISPR Effector Cas13X.1","volume":"260","author":"Li","year":"2023","journal-title":"Tohoku J. Exp. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"137861","DOI":"10.1016\/j.ijbiomac.2024.137861","article-title":"Characterizing the collateral activity of CRISPR\/Cas13 in mammalian cells: Implications for RNA editing and therapeutic applications","volume":"283","author":"Wan","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"11587","DOI":"10.1093\/nar\/gkae798","article-title":"Chem-CRISPR\/dCas9FCPF: A platform for chemically induced epigenome editing","volume":"52","author":"Altinbay","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/bs.mie.2025.01.010","article-title":"CRISPRoff epigenome editing for programmable gene silencing in human cell lines and primary T cells","volume":"712","author":"Pattali","year":"2025","journal-title":"Methods Enzymol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1093\/neuonc\/noaf055","article-title":"Multiplexed epigenetic memory editing using CRISPRoff sensitizes glioblastoma to chemotherapy","volume":"27","author":"Lin","year":"2025","journal-title":"Neuro-Oncology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13148-025-01913-0","article-title":"Epigenetic editing and epi-drugs: A combination strategy to simultaneously target KDM4 as a novel anticancer approach","volume":"17","author":"Sarno","year":"2025","journal-title":"Clin. Epigenet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"127397","DOI":"10.1016\/j.micres.2023.127397","article-title":"Inheritable CRISPR based epigenetic modification in a fungus","volume":"272","author":"Chen","year":"2023","journal-title":"Microbiol. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"10635","DOI":"10.1038\/s41467-024-54877-9","article-title":"Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity","volume":"15","author":"Hamouda","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"28311","DOI":"10.1021\/acsnano.4c09677","article-title":"Amplification of Protein Expression by Self-Amplifying mRNA Delivered in Lipid Nanoparticles Containing a \u03b2-Aminoester Ionizable Lipid Correlates with Reduced Innate Immune Activation","volume":"18","author":"Cui","year":"2024","journal-title":"ACS Nano"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.omtn.2019.12.004","article-title":"Improved Nucleic Acid Therapy with Advanced Nanoscale Biotechnology","volume":"19","author":"Weng","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Tanaka, H., Takata, N., Sakurai, Y., Yoshida, T., Inoue, T., Tamagawa, S., Nakai, Y., Tange, K., Yoshioka, H., and Maeki, M. (2021). Delivery of Oligonucleotides Using a Self-Degradable Lipid-Like Material. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13040544"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1021\/acs.molpharmaceut.2c00442","article-title":"Lipid Nanoparticle (LNP) Chemistry Can Endow Unique In Vivo RNA Delivery Fates within the Liver That Alter Therapeutic Outcomes in a Cancer Model","volume":"19","author":"Johnson","year":"2022","journal-title":"Mol. Pharm."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/mt.2009.91","article-title":"The Effect of Chemical Modification and Nanoparticle Formulation on Stability and Biodistribution of siRNA in Mice","volume":"17","author":"Gao","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1039\/D0BM01609H","article-title":"Helper lipid structure influences protein adsorption and delivery of lipid nanoparticles to spleen and liver","volume":"9","author":"Zhang","year":"2021","journal-title":"Biomater. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/acs.molpharmaceut.3c00561","article-title":"A Modular Albumin-Oligonucleotide Biomolecular Assembly for Delivery of Antisense Therapeutics","volume":"21","author":"Elkhashab","year":"2024","journal-title":"Mol. Pharm."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e2407742","DOI":"10.1002\/smll.202407742","article-title":"Photochemical Stabilization of Self-Assembled Spherical Nucleic Acids","volume":"21","author":"Kaviani","year":"2025","journal-title":"Small"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1038\/s41467-025-58523-w","article-title":"Liposomal lipid nanoparticles for extrahepatic delivery of mRNA","volume":"16","author":"Cheng","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1089\/hum.2024.106","article-title":"Lipid Nanoparticles for Nucleic Acid Delivery Beyond the Liver","volume":"35","author":"Saber","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"101436","DOI":"10.1016\/j.omtm.2025.101436","article-title":"Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism","volume":"33","author":"Bremmell","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e2500844","DOI":"10.1002\/advs.202500844","article-title":"Optimization of Lipid Nanoparticles with Robust Efficiency for the Delivery of Protein Therapeutics to Augment Cancer Immunotherapy","volume":"12","author":"Ren","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e03034","DOI":"10.1002\/smll.202503034","article-title":"Endogenous Corticosteroid Derived Lipid Nanoparticles (Cortico LNPs) Enable Selective mRNA Delivery to the Spleen","volume":"21","author":"Isaac","year":"2025","journal-title":"Small"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2200305","DOI":"10.1002\/adtp.202200305","article-title":"Tannic Acid Lipid Nanoparticles can Deliver Messenger RNA Payloads and Improve their Endosomal Escape","volume":"6","author":"Ma","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e03612","DOI":"10.1002\/adhm.202503612","article-title":"Structure\u2013Function Correlation of Clinically Inspired Lipid Nanoparticles for Lung and Spleen Targeted mRNA Delivery","volume":"15","author":"Martinez","year":"2026","journal-title":"Adv. Healthc. Mater."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1039\/D5MD00084J","article-title":"In vivo demonstration of enhanced mRNA delivery by cyclic disulfide-containing lipid nanoparticles for facilitating endosomal escape","volume":"16","author":"Kimura","year":"2025","journal-title":"RSC Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e202500878","DOI":"10.1002\/anie.202500878","article-title":"Ultrasound-Enhanced Spleen-Targeted mRNA Delivery via Fluorinated PEGylated Lipid Nanoparticles for Immunotherapy","volume":"64","author":"Chen","year":"2025","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1261\/rna.5160403","article-title":"Elevated activity of the large form of ADAR1 in vivo: Very efficient RNA editing occurs in the cytoplasm","volume":"9","author":"Wong","year":"2003","journal-title":"RNA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1089\/nat.2013.0454","article-title":"A chemical view of oligonucleotides for exon skipping and related drug applications","volume":"24","author":"Jarver","year":"2013","journal-title":"Nucleic Acid Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e2586","DOI":"10.21769\/BioProtoc.2586","article-title":"Cytosolic and Nuclear Delivery of CRISPR\/Cas9-ribonucleoprotein for Gene Editing Using Arginine Functionalized Gold Nanoparticles","volume":"7","author":"Mout","year":"2017","journal-title":"Bio-Protocol"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1089\/crispr.2024.0080","article-title":"Hairpin Internal Nuclear Localization Signals in CRISPR-Cas9 Enhance Editing in Primary Human Lymphocytes","volume":"8","author":"Noel","year":"2025","journal-title":"CRISPR J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"14645","DOI":"10.1039\/D2NR04281A","article-title":"Nuclear-targeted carbon quantum dot mediated CRISPR\/Cas9 delivery for fluorescence visualization and efficient editing","volume":"14","author":"Zhai","year":"2022","journal-title":"Nanoscale"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13073-017-0450-0","article-title":"Advances in the delivery of RNA therapeutics: From concept to clinical reality","volume":"9","author":"Kaczmarek","year":"2017","journal-title":"Genome Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ymeth.2017.04.003","article-title":"Genome editing via delivery of Cas9 ribonucleoprotein","volume":"121\u2013122","author":"DeWitt","year":"2017","journal-title":"Methods"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/17425247.2022.2100342","article-title":"Progress of delivery methods for CRISPR-Cas9","volume":"19","author":"Yang","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.apsb.2023.03.001","article-title":"mRNA delivery in cancer immunotherapy","volume":"13","author":"Zhong","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2300006","DOI":"10.1002\/anbr.202300006","article-title":"Ionizable Lipid Nanoparticles for mRNA Delivery","volume":"3","author":"Tang","year":"2023","journal-title":"Adv. NanoBiomed Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5966","DOI":"10.1021\/acsnano.4c09399","article-title":"Deciphering the Role of PEGylation on the Lipid Nanoparticle-Mediated mRNA Delivery to the Liver","volume":"19","author":"Gao","year":"2025","journal-title":"ACS Nano"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.addr.2020.06.014","article-title":"Polymeric vehicles for nucleic acid delivery","volume":"156","author":"Kauffman","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.2147\/IJN.S321329","article-title":"Recent Advances and Challenges in Gene Delivery Mediated by Polyester-Based Nanoparticles","volume":"16","author":"Piperno","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/17425247.2019.1663822","article-title":"Recent advances in polymeric materials for the delivery of RNA therapeutics","volume":"16","author":"Ulkoski","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"102728","DOI":"10.1016\/j.jddst.2021.102728","article-title":"Lipid- and Polymer-Based Nanoparticle Systems for the Delivery of CRISPR\/Cas9","volume":"65","author":"Ashok","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e2005222","DOI":"10.1002\/smll.202005222","article-title":"Active Delivery of CRISPR System Using Targetable or Controllable Nanocarriers","volume":"17","author":"Lyu","year":"2021","journal-title":"Small"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1208\/s12249-023-02576-x","article-title":"Highlights on Cell-Penetrating Peptides and Polymer-Lipid Hybrid Nanoparticle: Overview and Therapeutic Applications for Targeted Anticancer Therapy","volume":"24","author":"Bangera","year":"2023","journal-title":"AAPS PharmSciTech"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"14731","DOI":"10.18632\/oncotarget.4439","article-title":"Peptide-siRNA nanotherapeutics in arthritis","volume":"6","author":"Pham","year":"2015","journal-title":"Oncotarget"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e3107","DOI":"10.1002\/jgm.3107","article-title":"Delivery of CRISPR\/Cas9 for therapeutic genome editing","volume":"21","author":"Xu","year":"2019","journal-title":"J. Gene Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1021\/acs.accounts.5c00874","article-title":"Lipid\u2013Polymer Hybrid Nanoparticles (LPHNPs) for RNA Delivery","volume":"59","author":"Saiding","year":"2026","journal-title":"Acc. Chem. Res."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Duan, L., Ouyang, K., Xu, X., Xu, L., Wen, C., Zhou, X., Qin, Z., Xu, Z., Sun, W., and Liang, Y. (2021). Nanoparticle Delivery of CRISPR\/Cas9 for Genome Editing. Front. Genet., 12.","DOI":"10.3389\/fgene.2021.673286"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Mengstie, M.A. (2022). Viral Vectors for the in Vivo Delivery of CRISPR Components: Advances and Challenges. Front. Bioeng. Biotechnol., 10.","DOI":"10.3389\/fbioe.2022.895713"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1089\/hum.2024.258","article-title":"Trojan Horse-Like Vehicles for CRISPR-Cas Delivery: Engineering Extracellular Vesicles and Virus-Like Particles for Precision Gene Editing in Cystic Fibrosis","volume":"36","author":"Dipalo","year":"2025","journal-title":"Hum. Gene Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e13704","DOI":"10.7717\/peerj.13704","article-title":"Integrase deficient lentiviral vector: Prospects for safe clinical applications","volume":"10","author":"Yew","year":"2022","journal-title":"PeerJ"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jconrel.2020.09.003","article-title":"Adenoviral vectors for in vivo delivery of CRISPR-Cas gene editors","volume":"327","author":"Boucher","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13578-021-00662-w","article-title":"Potential of helper-dependent Adenoviral vectors in CRISPR-cas9-mediated lung gene therapy","volume":"11","author":"Bandara","year":"2021","journal-title":"Cell Biosci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1039\/D2BM00480A","article-title":"Cell-derived extracellular vesicles for CRISPR\/Cas9 delivery: Engineering strategies for cargo packaging and loading","volume":"10","author":"Liang","year":"2022","journal-title":"Biomater. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"102040","DOI":"10.1016\/j.omtn.2023.102040","article-title":"CRISPR-Cas9 delivery strategies with engineered extracellular vesicles","volume":"34","author":"Lu","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.apsb.2023.10.004","article-title":"Engineered extracellular vesicles efficiently deliver CRISPR-Cas9 ribonucleoprotein (RNP) to inhibit herpes simplex virus1 infection in vitro and in vivo","volume":"14","author":"Wan","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e12389","DOI":"10.1002\/jev2.12389","article-title":"Extracellular vesicle-mediated delivery of CRISPR\/Cas9 ribonucleoprotein complex targeting proprotein convertase subtilisin-kexin type 9 (Pcsk9) in primary mouse hepatocytes","volume":"13","author":"Ilahibaks","year":"2024","journal-title":"J. Extracell. Vesicles"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Zhu, X., Gao, M., Yang, Y., Li, W., Bao, J., and Li, Y. (2023). The CRISPR\/Cas9 System Delivered by Extracellular Vesicles. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15030984"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.semcancer.2023.10.002","article-title":"Extracellular vesicles as a potential delivery platform for CRISPR-Cas based therapy in epithelial ovarian cancer","volume":"96","author":"Godbole","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"113853","DOI":"10.1016\/j.jconrel.2025.113853","article-title":"Modulating binding affinity of aptamer-based loading constructs enhances extracellular vesicle-mediated CRISPR\/Cas9 delivery","volume":"384","author":"Hegeman","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1038\/s41467-024-45795-x","article-title":"Orthogonal inducible control of Cas13 circuits enables programmable RNA regulation in mammalian cells","volume":"15","author":"Ding","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41467-017-00644-y","article-title":"Rapid and reversible epigenome editing by endogenous chromatin regulators","volume":"8","author":"Braun","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1089\/crispr.2021.0134","article-title":"Electroporation-Mediated Delivery of Cas9 Ribonucleoproteins Results in High Levels of Gene Editing in Primary Hepatocytes","volume":"5","author":"Rathbone","year":"2022","journal-title":"CRISPR J."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/nchembio.2179","article-title":"A chemical-inducible CRISPR\u2013Cas9 system for rapid control of genome editing","volume":"12","author":"Liu","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.molcel.2020.03.033","article-title":"CRISPR-Cas13 Inhibitors Block RNA Editing in Bacteria and Mammalian Cells","volume":"78","author":"Lin","year":"2020","journal-title":"Mol. Cell"},{"key":"ref_98","first-page":"e62245","article-title":"Delivery of the Cas9\/sgRNA Ribonucleoprotein Complex in Immortalized and Primary Cells via Virus-like Particles (\u201cNanoblades\u201d)","volume":"169","author":"Mangeot","year":"2021","journal-title":"J. Vis. Exp."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e2309431","DOI":"10.1002\/smll.202309431","article-title":"Iron-Confined CRISPR\/Cas9-Ribonucleoprotein Delivery System for Redox-Responsive Gene Editing","volume":"20","author":"Qiu","year":"2024","journal-title":"Small"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"13790","DOI":"10.1021\/acsnano.4c16617","article-title":"Lipid Nanoparticles for In Vivo Lung Delivery of CRISPR-Cas9 Ribonucleoproteins Allow Gene Editing of Clinical Targets","volume":"19","author":"Haley","year":"2025","journal-title":"ACS Nano"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/s41591-018-0137-0","article-title":"A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells","volume":"24","author":"Vakulskas","year":"2018","journal-title":"Nat. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41467-024-44867-2","article-title":"Programmable RNA base editing with photoactivatable CRISPR-Cas13","volume":"15","author":"Yu","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e202320029","DOI":"10.1002\/anie.202320029","article-title":"Small Molecule-Inducible and Photoactivatable Cellular RNA N1-Methyladenosine Editing","volume":"63","author":"Xie","year":"2024","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ymthe.2024.12.032","article-title":"Low-inflammatory lipid nanoparticle-based mRNA vaccine elicits protective immunity against H5N1 influenza virus with reduced adverse reactions","volume":"33","author":"Kawai","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1021\/acsnano.6b07600","article-title":"Direct Cytosolic Delivery of CRISPR\/Cas9-Ribonucleoprotein for Efficient Gene Editing","volume":"11","author":"Mout","year":"2017","journal-title":"ACS Nano"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"McDowall, S., Aung-Htut, M., Wilton, S., and Li, D. (2024). Antisense oligonucleotides and their applications in rare neurological diseases. Front. Neurosci., 18.","DOI":"10.3389\/fnins.2024.1414658"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.actbio.2019.12.005","article-title":"siRNA release kinetics from polymeric nanoparticles correlate with RNAi efficiency and inflammation therapy via oral delivery","volume":"103","author":"He","year":"2020","journal-title":"Acta Biomater."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jconrel.2024.04.018","article-title":"Cardiac delivery of modified mRNA using lipid nanoparticles: Cellular targets and biodistribution after intramyocardial administration","volume":"369","author":"Labonia","year":"2024","journal-title":"J. Control. Release"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jconrel.2024.01.011","article-title":"Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease","volume":"367","author":"Caron","year":"2024","journal-title":"J. Control. Release"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"gkag484","DOI":"10.1093\/nar\/gkag484","article-title":"Enhanced splicing modulation by NMA-modified antisense oligonucleotides","volume":"54","author":"Ling","year":"2026","journal-title":"Nucleic Acids Res."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Zhai, D., Ni, J., Shao, X., Zhao, W., Chen, Y., Fan, K., Li, J., Shen, Y., Lin, A., and Hu, W. (2026). Lipid nanoparticle-delivered ornithine transcarbamylase mRNA alleviates liver fibrosis in preclinical models. Hepatology.","DOI":"10.1097\/HEP.0000000000001708"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1089\/nat.2016.0652","article-title":"Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy","volume":"27","author":"Shabanpoor","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jconrel.2023.07.027","article-title":"Delivery of mutant huntingtin-lowering antisense oligonucleotides to the brain by intranasally administered apolipoprotein A-I nanodisks","volume":"360","author":"Aly","year":"2023","journal-title":"J. Control. Release"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"100929","DOI":"10.1016\/j.neo.2023.100929","article-title":"Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma","volume":"44","author":"Han","year":"2023","journal-title":"Neoplasia"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"16432","DOI":"10.1021\/acsnano.2c12857","article-title":"Engineered Extracellular Vesicle-Delivered CRISPR\/Cas9 for Radiotherapy Sensitization of Glioblastoma","volume":"17","author":"Liu","year":"2023","journal-title":"ACS Nano"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"7186","DOI":"10.1039\/C5TB01377A","article-title":"Gene silencing of the pro-inflammatory cytokine TNF-\u03b1 with siRNA delivered by calcium phosphate nanoparticles, quantified by different methods","volume":"3","author":"Neuhaus","year":"2015","journal-title":"J. Mater. Chem. B"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Goudy, L., Ha, A., Borah, A.A., Umhoefer, J.M., Chow, L., Tran, C., Winters, A., Talbot, A., Hernandez, R., and Li, Z. (2025). Integrated epigenetic and genetic programming of primary human T cells. Nat. Biotechnol.","DOI":"10.1038\/s41587-025-02856-w"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"6492","DOI":"10.1039\/D2BM02103J","article-title":"Targeted microRNA delivery by lipid nanoparticles and gas vesicle-assisted ultrasound cavitation to treat heart transplant rejection","volume":"11","author":"Wang","year":"2023","journal-title":"Biomater. Sci."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-1-4939-7352-1_15","article-title":"Dobrovolskaia, Analysis of Pro-inflammatory Cytokine and Type II Interferon Induction by Nanoparticles","volume":"1682","author":"Potter","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"105218","DOI":"10.1016\/j.nbd.2020.105218","article-title":"Exosome-mediated delivery of antisense oligonucleotides targeting \u03b1-synuclein ameliorates the pathology in a mouse model of Parkinson\u2019s disease","volume":"148","author":"Yang","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jconrel.2022.01.027","article-title":"Delivery of modified mRNA to damaged myocardium by systemic administration of lipid nanoparticles","volume":"343","author":"Evers","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"113623","DOI":"10.1016\/j.jconrel.2025.113623","article-title":"Effective transcatheter intracoronary delivery of mRNA-lipid nanoparticles targeting the heart","volume":"381","author":"Handa","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/01902148.2026.2633914","article-title":"Targeted delivery of Follistatin-like 1 siRNA via biodegradable nanoparticles attenuates bleomycin-induced pulmonary fibrosis in mice","volume":"52","author":"Li","year":"2026","journal-title":"Exp. Lung Res."},{"key":"ref_124","first-page":"1179","article-title":"Decoding Aging through iPSC Reprogramming: Advances and Challenges","volume":"17","author":"Li","year":"2025","journal-title":"Aging Dis."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"5885","DOI":"10.1021\/acs.nanolett.8b02578","article-title":"Nanoparticle Delivery of miRNA-21 Mimic to Cardiac Macrophages Improves Myocardial Remodeling after Myocardial Infarction","volume":"18","author":"Bejerano","year":"2018","journal-title":"Nano Lett."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s13346-020-00744-1","article-title":"Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation","volume":"10","author":"Taha","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s43586-023-00258-3","article-title":"Best practices for characterizing RNA lipid nanoparticles","volume":"3","author":"Khan","year":"2023","journal-title":"Nat. Rev. Methods Prim."},{"key":"ref_128","first-page":"101092","article-title":"Critical quality attributes of lipid nanoparticles and in vivo fate","volume":"20","author":"Di","year":"2025","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s42004-025-01699-5","article-title":"Spotlighting the criticality of lipid quality control through a mechanistic investigation of mRNA activity loss in lipid nanoparticles","volume":"8","author":"Kang","year":"2025","journal-title":"Commun. Chem."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1021\/acsami.4c20077","article-title":"Transfection Potency of Lipid Nanoparticles Containing mRNA Depends on Relative Loading Levels","volume":"17","author":"Liao","year":"2025","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/hgtb.2017.246","article-title":"In Vivo Potency Assay for Adeno-Associated Virus\u2013Based Gene Therapy Vectors Using AAVrh.10 as an Example","volume":"29","author":"De","year":"2018","journal-title":"Hum. Gene Ther. Methods"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"118226","DOI":"10.1016\/j.bios.2025.118226","article-title":"Stability-preserving post-processing of mRNA\u2013lipid nanoparticles utilizing a scalable ion concentration polarization platform","volume":"294","author":"Yoon","year":"2026","journal-title":"Biosens. Bioelectron."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jconrel.2016.05.059","article-title":"Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA","volume":"235","author":"Chen","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41434-024-00444-2","article-title":"Analytical characterization of full, intermediate, and empty AAV capsids","volume":"31","author":"Dollive","year":"2024","journal-title":"Gene Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.molcel.2023.01.010","article-title":"Reversing the Central Dogma: RNA-guided control of DNA in epigenetics and genome editing","volume":"83","author":"Chang","year":"2023","journal-title":"Mol. Cell"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"New Engl. J. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1038\/s41467-018-04048-4","article-title":"RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors","volume":"9","author":"Thakore","year":"2018","journal-title":"Nat. Commun."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/14\/6467\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T08:18:37Z","timestamp":1784621917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/14\/6467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":137,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["ijms27146467"],"URL":"https:\/\/doi.org\/10.3390\/ijms27146467","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]}}}